Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:30:58.219Z.
Calculation as of: 2026-10-06T13:30:58.219Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9f8c720c17565e189db9218018d8859aabec9e8167d5f057fd0cc602bb9808d0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$484.56M
EV/EBIT Ratio
N/A
TTM Avg
5.92x
3Y Avg
17.76x
5Y Avg
17.76x
Market Cap
$488.09M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$458.01M
EV/EBIT Ratio
N/A
TTM Avg
84.81x
3Y Avg
33.20x
5Y Avg
21.83x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cerus Corporation (CERS) | $477.61M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $483.26M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $484.56M | N/A | 5.92x | 17.76x | 17.76x |
| NRC Health (NRC)vs › | $470.12M | 37.79x | 22.84x | 18.67x | 19.86x |
| Bright Minds Biosciences Inc. (DRUG)vs › | $488.09M | N/A | N/A | N/A | N/A |
| Kamada Ltd. (KMDA)vs › | $465.02M | 16.07x | 15.53x | 17.24x | 21.68x |
| Evolus, Inc. (EOLS)vs › | $491.93M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $458.01M | N/A | 84.81x | 33.20x | 21.83x |
| Assembly Biosciences, Inc. (ASMB)vs › | $452.63M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
